Workflow
CTO
icon
Search documents
Combined General Meeting of July 22, 2025 Conditions for Obtaining the Preparatory Documents
Globenewswire· 2025-07-01 16:00
Core Points - Soitec will hold its Annual General Meeting on July 22, 2025, at 9:30 a.m. Paris time in Paris, France [1] - The preliminary meeting notice was published in the French legal gazette on June 13, 2025, including the agenda and draft resolutions [2] - The convening notice will be published on July 4, 2025, and all related documents are available on the company's website [3] - Shareholders can request additional documents up to five days before the meeting, with specific instructions provided [4] - The General Meeting will be broadcast live on Soitec's website and available for replay [5] - The first-quarter 2025-2026 revenue will be announced on July 22, 2025, after market close [6] Company Overview - Soitec is a world leader in innovative semiconductor materials, with over 30 years of experience in developing high-performance and energy-efficient products [7] - The company operates in three strategic markets: mobile communications, automotive and industry, and smart devices, employing 2,300 people from 50 different nationalities [7] - Soitec has registered more than 4,100 patents, highlighting its strong position in the semiconductor value chain [7]
CEF: Still A Great Way To Play Precious Metals
Seeking Alpha· 2025-07-01 10:46
Group 1 - The investor has 15 years of experience in financial services, focusing on macro trends and identifying undervalued sectors and thematic investment opportunities such as metals, gold, and cryptocurrency [1] - The investor emphasizes the importance of diligent saving and investing, highlighting a personal journey from a middle-class background to co-managing a seven-figure investment account [2] - The investor maintains an updated portfolio that includes a variety of funds, stocks, and sectors, demonstrating a commitment to transparency and active management [3] Group 2 - The broad market investments include DIA, VOO, QQQM, and RSP, while sector-specific investments focus on energy (XLE/IXC) and utilities (VPU/IDU/BUI) [3] - Alternative investments include Bitcoin and gold (IAU), indicating a diversification strategy that encompasses both traditional and digital assets [3] - The investor is involved in the CEF/ETF Income Laboratory, which targets safe and reliable yields of approximately 8% through managed income portfolios, appealing to both active and passive investors [3]
X @外汇交易员
外汇交易员· 2025-07-01 03:26
#数据 韩国据产业通商资源部数据显示,6月出口同比增4.3%,达到598.0亿美元,但略低于4.7%的预期中值。韩国5月出口下降1.3%。韩国6月对美国出口下降0.5%,连续第3个月减少;对中国出口连续第2个月下降,降幅为2.7%;对欧盟出口增长14.7%,对东南亚国家的出口增长2.1%。韩国半导体出口连续第4个月增长,增幅11.6%,但为近4个月以来最慢增长。 ...
中国晶圆制造设备行业的现状与未
2025-07-01 00:40
更多资料加入知识星球:水木调研纪要 关注公众号:水木Alpha China's Wafer Fab Equipment Industry Present & Future Covering the present tools & future roadmap of NAURA, AMEC, ACM Research, SiCarrier and Piotech ZEPHYR JUN 29, 2025 5 Share Source: CGTN The advent of LLMs and the intensication of the US-China rivalry have placed semiconductors at the undisputed center of global power dynamics. While headlines frequently focus on the progress of Chinese chip designers like Huawei and foundries such as SMIC and CXMT, a critical yet far mor ...
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-01435, a Long-Acting Corticotropin-Releasing Factor Type 1 Receptor Antagonist
Prnewswire· 2025-06-30 20:05
Core Insights - Neurocrine Biosciences has initiated a Phase 1 first-in-human clinical study for the investigational compound NBIP-01435, aimed at treating congenital adrenal hyperplasia (CAH) [1][2] - NBIP-01435 is a long-acting corticotropin-releasing factor type 1 receptor antagonist, which may improve androgen control and allow for lower glucocorticoid dosing [3] - The company has a strong commitment to expanding treatment options for CAH, with NBIP-01435 being the first investigational peptide from its biologics pipeline to enter clinical trials [2][4] Company Overview - Neurocrine Biosciences is a leading biopharmaceutical company focused on neuroscience, dedicated to developing treatments for neurological, neuroendocrine, and neuropsychiatric disorders [5] - The company has a diverse portfolio that includes FDA-approved treatments for various conditions, including CAH, and a robust pipeline with multiple compounds in mid- to late-phase clinical development [5] - In December 2024, Neurocrine received FDA approval for crinecerfont, marking the first new treatment for CAH in 70 years [3]
Chip “Make in Vietnam”: VIẾT TIẾP GIẤC MƠ CỦA CHA ANH | Vinh Quang Nguyễn | TEDxFTU Hanoi
TEDx Talks· 2025-06-30 16:46
Để bắt đầu về cái bài nói ngày hôm nay thì tôi muốn kể với các bạn về cái câu chuyện một cái hành trình của hạt gạo. Việt Nam chúng ta có một cái câu chuyện rất hay, rất đáng tự hào đấy là hành trình hạt gạo. À nếu Việt Nam là nước nông nghiệp của ngô nước và các cái hệ trước của chúng ta, thế hệ tra anh, thế hệ trước nữa đã cố gắng để phát triển Việt Nam đưa cái nền nông nghiệp ngôn nước của chúng ta để phát triển.À ở thời điểm hiện tại năm 2024 thì chúng ta sẽ đạt được khoảng năm sân khẩu khoảng 5 triệu 8 ...
Apollo's Torsten Slok: Peak uncertainty is behind us, but these risk factors are still on horizon
CNBC Television· 2025-06-30 15:31
Welcome back. The S&P 500 NASDAQ hitting record highs this morning as we close out the first half of the year. Joining us now, Apollo global management chief economist Torson Sllock to give his outlook for the economy in the second half of the year.Torson, very good morning to you. Good to see you. Thanks for having me.Um, just that snapshot on what we learned there from Kevin Hasset and the developments over the weekend. Is is your expectation that the big beautiful bill ultimately does whether it's this w ...
估值超1600亿,长江存储母公司获员工持股平台入股
Guan Cha Zhe Wang· 2025-06-30 15:09
Core Viewpoint - Changjiang Storage's parent company, Changjiang Storage Technology Holding Co., Ltd. (Chang控集团), has undergone a change in its business registration, increasing its registered capital from 111.81207 billion to 113.27896 billion yuan, marking an increase of approximately 1.467 billion yuan [1]. Group 1: Shareholder Changes - New shareholders include Wuhan Smart Chip Plan No. 1 Enterprise Management Partnership (Limited Partnership) holding 0.2295% and Wuhan Smart Chip Plans No. 2 to No. 6, each holding 0.2131%, totaling 1.295% with a subscribed capital of 1.4668966 million yuan [2]. - The new shareholders are structured in a dual-layer nested format, with the second to fifth partnerships having a total of 24 underlying partnerships, all named under the "Smart Chip Plan" [2]. Group 2: Employee Stock Ownership Plan - The newly added Smart Chip Plan serves as an employee stock ownership platform primarily for senior management and technical staff of Chang控集团 [5]. - An increase of 2.127 billion yuan (1.295% of total registered capital) is planned for the employee stock ownership platform, which is currently in preparation [5]. Group 3: Company Valuation and Business Overview - Chang控集团's valuation is estimated to reach 164.25 billion yuan, with its core business encompassing the R&D and production of 3D NAND flash memory, embedded storage chips, and solid-state drives [5]. - Changjiang Storage has been recognized as a significant flash memory manufacturer in China, recently entering the Hurun Research Institute's 2025 Global Unicorn List with a valuation of 160 billion yuan [5]. Group 4: Recent Investments - On April 25, 2023, Huangyuan Zhihui Beverage Co., Ltd. announced a 1.6 billion yuan investment in Chang控集团, resulting in a 0.99% stake [6]. - Following the entry of the employee stock ownership platform, the number of shareholders in Chang控集团 has expanded to 29, diluting the holdings of existing shareholders [6].
帮主郑重:7月A股吃肉攻略!三大主线+避险策略全解析
Sou Hu Cai Jing· 2025-06-30 15:03
各位兄弟姐妹们,我是帮主郑重,干了20年财经记者,现在更爱跟大家唠唠接地气的投资干货。今儿个咱们不聊虚的,直接上硬菜——7月A股到底咋走? 哪些板块能吃肉?咱们普通散户该咋操作? 先给大家吃颗定心丸:券商圈现在基本达成共识,7月A股大概率震荡上行!上证指数刚突破3400点,就像开车上了高速,短期刹车可能性不大。为啥?你 看啊,国内政策暖风频吹,科创板改革、IPO预审阅这些大招,摆明了要给市场输血;国外呢,美联储降息预期升温,中东局势也缓和了,资金正从避险资 产往股市里钻。 不过咱得先搞清楚,这波行情不是普涨,而是结构性机会。啥意思?就像吃火锅,有人爱吃麻辣锅,有人爱菌汤锅,A股7月就是各板块轮流"涮肉"。根据 十大券商的观点,我给大家划三个重点方向: 第一,科技硬菜管够吃。 AI、算力、半导体这些科技股,现在就像刚出锅的毛肚,又嫩又脆。你想啊,三季度科技企业IPO重启,产品催化一个接一个,资金不炒它们炒谁?而且科 创板改革后,未盈利的科技公司也能上市,这相当于给科技板块加了把火。具体咋选?可以盯着光模块、PCB这些海外算力产业链的细分领域,还有国产算 力、机器人这些代表未来趋势的方向。 第二,金融搭台稳军心。 ...
ASML's High-NA Progress Amazes: Can Early Trials Turn to Mass Demand?
ZACKS· 2025-06-30 13:36
Core Insights - ASML Holding N.V. is advancing its High-NA EUV lithography systems, crucial for the future of advanced chipmaking, with the fifth NXE:5000 system shipped in Q1 2025 and deliveries of the NXE:5200 model starting in Q2 2025 [1][9] Group 1: Technology and Customer Feedback - The High-NA systems enable chipmakers to produce smaller and more complex features with fewer steps and improved yields, receiving positive feedback from major clients like Intel and Samsung [2] - Intel reported over 30,000 wafers exposed in a single quarter using the High-NA tool, reducing process steps from 40 to less than 10, while Samsung achieved a 60% reduction in cycle time on one layer [3] Group 2: Adoption Phases and Future Outlook - ASML's High-NA technology is currently in phase one, focused on research and development, with mass production expected to begin around 2026-2027, followed by full adoption in later phases [4][9] - The company is working to enhance tool productivity and reliability in real-world applications, positioning itself to lead the next phase of semiconductor innovation [5] Group 3: Competitive Landscape - Competitors like Applied Materials and KLA Corporation are also significant players in advanced chipmaking tools, focusing on complementary technologies that could benefit from ASML's High-NA rollout [6][7] Group 4: Financial Performance and Valuation - ASML's shares have increased approximately 14.8% year-to-date, outperforming the Zacks Computer and Technology sector's 6.1% gain [8] - The Zacks Consensus Estimate for ASML's earnings indicates a year-over-year increase of about 31.6% for 2025 and 11.1% for 2026, with recent upward revisions for 2025 estimates [11] - ASML trades at a forward price-to-sales ratio of 8.2, higher than the sector average of 6.62 [13]